Research progress on advanced therapeutic approaches and emerg-ing technologies in the drug treatment of refractory thyroid cancer
10.12092/j.issn.1009-2501.2025.03.004
- VernacularTitle:难治性甲状腺癌药物治疗新技术和新方法的研究进展
- Author:
Hongdan CHEN
1
;
Yinde HUANG
;
Chong LI
Author Information
1. 重庆大学附属人民医院,重庆市人民医院乳腺甲状腺外科,重庆 401147;西南大学药学院,重庆 400715
- Publication Type:Journal Article
- Keywords:
refractory thyroid cancer;
molecular targeted therapy;
immunotherapy;
radiopharma-ceutical therapy;
nanotechnology
- From:
Chinese Journal of Clinical Pharmacology and Therapeutics
2025;30(3):325-331
- CountryChina
- Language:Chinese
-
Abstract:
Poorly differentiated and advanced thyroid cancers are characterized by high malignan-cy,progress rapidly,and resistance to radiotherapy and chemotherapy.These characteristics pose sig-nificant challenges,severely limiting effective treat-ment options.Various kinase inhibitors have been used in the treatment of refractory thyroid cancer were used accompanying by the carcinogenic mechanisms'studies investigating in thyroid cancer,such as Dabrafenib(BRAF inhibitor),Trametinib(MEK inhibitor),Vandetanib(RET inhibitor),Lenva-tinib(VEGF inhibitor),and multi-target kinase inhib-itors.However,drug resistance remains an inevita-ble issue,significantly limiting the efficacy and ap-plication of kinase inhibitors.Therapeutic approach-es such as immunotherapy,redifferentiation strate-gies for thyroid cancer,radiopharmaceutical conju-gates,and the application of nanotechnology are currently in the clinical research stage,requiring further clarification of their efficacy.Comprehen-sive understanding of therapeutic strategies and available treatment combinations for refractory thy-roid cancer is of paramount importance in the diag-nosis and treatment of thyroid cancer.Therefore,this article reviews technologies and methods for treating refractory thyroid cancer,focusing on che-motherapy,molecular targeted therapy,immuno-therapy,and radiopharmaceutical therapy,aiming to provide a reference for selecting treatment strat-egies for refractory thyroid cancer.
